格隆汇11月20日丨和黄医药(00013.HK)今天宣布,胡朝红获委任为公司独立非执行董事及技术委员会成员,自 2024 年 11 月 21 日起生效。胡博士在治疗性抗体、抗体偶联药物及疫苗开发方面拥有超过 20 年经验。在她的职业生涯中,她展现坚强的领导及创新能力,带领多项研发计划。胡博士的专业知识涵盖早期发现以至临床开发及商业化。她亦拥有成功业务发展及建立策略伙伴关系(包括对外许可及合作)的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.